Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
About Hemophilia
Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.
Technavio’s analysts forecast the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Baxalta
• Bayer
• CSL Behring
• Novo Nordisk
• Pfizer
Other prominent vendors
• Alnylam Pharmaceuticals
• Amarna Therapeutics
• Asklepios BioPharmaceutical
• Biogen
• BioMarin
• Catalyst Bioscience
• Chiesi Farmaceutici
• Dimension Therapeutics
• Emergent BioSolutions
• F. Hoffmann-La Roche
• Grifols, Kedrion Biopharma
• Octapharma
• rEVO Biologics
• OPKO Biologics
• Sangamo Biosciences
• Spark Therapeutics
• Swedish Orphan Biovitrum
• UniQure Biopharma.
Market driver
• Focus on prophylactic treatment
• For a full, detailed list, view our report
Market challenge
• Low diagnosis rate
• For a full, detailed list, view our report
Market trend
• Increase in technological innovations
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.
Technavio’s analysts forecast the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Baxalta
• Bayer
• CSL Behring
• Novo Nordisk
• Pfizer
Other prominent vendors
• Alnylam Pharmaceuticals
• Amarna Therapeutics
• Asklepios BioPharmaceutical
• Biogen
• BioMarin
• Catalyst Bioscience
• Chiesi Farmaceutici
• Dimension Therapeutics
• Emergent BioSolutions
• F. Hoffmann-La Roche
• Grifols, Kedrion Biopharma
• Octapharma
• rEVO Biologics
• OPKO Biologics
• Sangamo Biosciences
• Spark Therapeutics
• Swedish Orphan Biovitrum
• UniQure Biopharma.
Market driver
• Focus on prophylactic treatment
• For a full, detailed list, view our report
Market challenge
• Low diagnosis rate
• For a full, detailed list, view our report
Market trend
• Increase in technological innovations
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
